Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses

References

• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA -19 vaccine. N Engl J Med. 2020;383:2603–2615.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021;385:2348–2360.
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:213–222.
   PubMed Web of Science ®Google Scholar
• Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. Jama. 2021;326:35–45.
   PubMed Web of Science ®Google Scholar
• Favresse J, Bayart JL, Mullier F, et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect. 2021;10:1495–1498.
   PubMed Web of Science ®Google Scholar
• Khoury J, Najjar-Debbiny R, Hanna A, et al. COVID-19 vaccine - long term immune decline and breakthrough infections. Vaccine. 2021;39:6984–6989.
   PubMed Web of Science ®Google Scholar
• Lipsitch M, Krammer F, Regev-Yochay G, et al. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol. 2022;22:57–65.
   PubMed Web of Science ®Google Scholar
• Menni C, May A, Polidori L, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID study. Lancet Infect Dis. 2022;22:1002–1010.
   PubMed Web of Science ®Google Scholar
• Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022;22:483–495.
   PubMed Web of Science ®Google Scholar
• Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258–2276.
   PubMed Web of Science ®Google Scholar
• Stuart ASV, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet. 2022;399:36–49.
   PubMed Web of Science ®Google Scholar
• Kanokudom S, Assawakosri S, Suntronwong N, et al. Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine. Vaccines (Basel). 2022;10:86
   PubMed Web of Science ®Google Scholar
• Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398:2093–2100.
   PubMed Web of Science ®Google Scholar
• Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009;21:346–351.
   PubMed Web of Science ®Google Scholar
• Vaine M, Wang S, Crooks ET, et al. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol. 2008;82:7369–7378.
   PubMed Web of Science ®Google Scholar
• Wang S, Yates NL, Pollara J, et al. Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV. NPJ Vaccines. 2022;7:18.
   PubMed Web of Science ®Google Scholar
• He Q, Mao Q, An C, et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021;10:629–637.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhao Z, Cui T, et al. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants. Emerg Microbes Infect. 2022;11:829–840.
   PubMed Web of Science ®Google Scholar
• Jiang HD, Guo XL, Jin PF, et al. Head-to-head comparisons of the neutralizing antibody against SARS-CoV-2 variants elicited by four priming-boosting regimens. Emerg Microbes Infect. 2022;11:1751–1753.
   PubMed Web of Science ®Google Scholar
• Li JX, Wu SP, Guo XL, et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir Med. 2022;10:739–748.
   PubMed Web of Science ®Google Scholar
• Wang S, Kennedy JS, West K, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine. 2008;26:3947–3957.
   PubMed Web of Science ®Google Scholar
• Li Y, Bi Y, Xiao H, et al. A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques. Emerg Microbes Infect. 2021;10:342–355.
   PubMed Web of Science ®Google Scholar